wp1066 Search Results


95
MedChemExpress wp1066
( A ) Schema of the treatment of immunocompetent mice that underwent i.c. implantation of GL261 glioma cells. Seven days after GL261 implantation, mice were treated with <t>WP1066</t> (60 mg/kg) by oral gavage (o.g.) 3 times per week (M/W/F) for 3 weeks. On day 7, mice were treated intratumorally with the STING agonist 8803 (5 μg). The survival rate of C57BL/6J mice was estimated by the Kaplan-Meier method. Control: 11 mice (median survival [MS]: 18 days), WP1066: 8 mice (MS: 21 days), 8803: 8 mice (MS: 143.5 days); 4 long-term survivor), WP1066 + 8803 agonist: 7 mice (MS: 25 days). Statistics (log-rank test): control versus WP1066 P = 0.0047; control versus 8803 P < 0.0001; control versus WP1066 + 8803 P = 0.0002; WP1066 versus WP1066 + 8803 P = 0.02; 8803 versus WP1066 + 8803 P = 0.0005; 8803 versus WP1066 P < 0.0001. ( B ) In vitro luciferase expression assay for the induction of IFN responses. Various concentrations of the STING agonist 8803 were used to induce the luciferase expression in the top panels. A physiological (2 μM) and a high dose (5 μM) of WP1066 was used in combination. Direct cellular cytotoxicity was measured during the above experimental conditions (lower panels). At a WP1066 concentration of 5 μM, there was a decrease in IFN activity, which was not attributed to cell viability. ( C ) WP1066 decreases STING protein expression in THP-1 cells in a dose-dependent manner. THP-1 cells were treated with the indicated concentrations of WP1066. Cells were collected and analyzed by Western blotting. ( D ) Ubiquitination assay of STING in THP-1 cells indicates that WP1066 induces STING ubiquitination in a dose-dependent manner. MG132, proteasome inhibitor used in all conditionsl; IB, immunoblotting; UB, ubiquitination blotting; IP, immunoprecipitation.
Wp1066, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/WP1066/pmc11178548-237-0-11
Average 95 stars, based on 1 article reviews
wp1066 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

97
TargetMol jak2 stat3 inhibitor
IL-6 promotes LUAD progression by activating <t>the</t> <t>JAK2/STAT3</t> pathway in M2-like macrophages. a GSVA analysis of differential pathways between AMs, TAMs in early and advanced LUAd. b Effects of IL-6 stimulation on common pathway expression in TAMs detected by western blot analysis. c Expression of the JAK2/STAT3 pathway with IL-6-stimulated, IL-6-stimulated with the addition of IL-6-NA in M2-like macrophages were analyzed by western blot. d Effect of AZD1480 and WP1066 on JAK2/STAT3 pathway expression in THP1 derived M2-like macrophages after IL-6 stimulation were analyzed by western blot. e Cell migration and invasion ability of LUAD cells alone, co-culture with M2-like macrophages or co-culture with M2-like macrophages followed by addition of AZD1480 and WP1066 was determined by the transwell assay. f RT-qPCR and Elisa analysis showed IL-6 expression in M2-like macrophages after IL-6 stimulation or IL-6 stimulation with the addition of AZD1480 and WP1066 (Left: Elisa results. Right: RT-qPCR results). g IL-6 expression after STAT3 overexpression or knockdown was analyzed by western blot. h RT-qPCR and Elisa analysis showed IL-6 expression in M2-like macrophages after STAT3 overexpression or knockdown
Jak2 Stat3 Inhibitor, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/WP1066/pmc10903044-99-0-5
Average 97 stars, based on 1 article reviews
jak2 stat3 inhibitor - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

94
Selleck Chemicals stat3 inhibitor wp1066
Figure 3. NF-YA increases the expression of VEGF and activity of <t>STAT3.</t> (A) NF-YA, VEGF and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells (left panel); relative mRNA expression of VEGF in vector control or NF-YA stably overexpressed A375P/Malme-3M cells by real-time quantitative PCR (left panel), *P<0.003 compared with the control group. (B) STAT3, pY-STAT3 (tyrosine phosphorylated STAT3 at the 705 residue) and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells. (C) Immunofluorescence staining showing expression of pY-STAT3 (red) in vector control or NF-YA stably overexpressed A375P cells. Nuclei were stained with DAPI (blue).
Stat3 Inhibitor Wp1066, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/WP1066/pm27109360-56-0-10
Average 94 stars, based on 1 article reviews
stat3 inhibitor wp1066 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology sc 203282
Figure 3. NF-YA increases the expression of VEGF and activity of <t>STAT3.</t> (A) NF-YA, VEGF and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells (left panel); relative mRNA expression of VEGF in vector control or NF-YA stably overexpressed A375P/Malme-3M cells by real-time quantitative PCR (left panel), *P<0.003 compared with the control group. (B) STAT3, pY-STAT3 (tyrosine phosphorylated STAT3 at the 705 residue) and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells. (C) Immunofluorescence staining showing expression of pY-STAT3 (red) in vector control or NF-YA stably overexpressed A375P cells. Nuclei were stained with DAPI (blue).
Sc 203282, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/Stat3+Inhibitor+III%2C+WP1066/pm38367463-73-18-21
Average 93 stars, based on 1 article reviews
sc 203282 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Merck KGaA wp1066
Figure 3. NF-YA increases the expression of VEGF and activity of <t>STAT3.</t> (A) NF-YA, VEGF and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells (left panel); relative mRNA expression of VEGF in vector control or NF-YA stably overexpressed A375P/Malme-3M cells by real-time quantitative PCR (left panel), *P<0.003 compared with the control group. (B) STAT3, pY-STAT3 (tyrosine phosphorylated STAT3 at the 705 residue) and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells. (C) Immunofluorescence staining showing expression of pY-STAT3 (red) in vector control or NF-YA stably overexpressed A375P cells. Nuclei were stained with DAPI (blue).
Wp1066, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/wp1066/pmc08946000-85-59-54
Average 90 stars, based on 1 article reviews
wp1066 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
CH Instruments wp1066
Figure 3. NF-YA increases the expression of VEGF and activity of <t>STAT3.</t> (A) NF-YA, VEGF and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells (left panel); relative mRNA expression of VEGF in vector control or NF-YA stably overexpressed A375P/Malme-3M cells by real-time quantitative PCR (left panel), *P<0.003 compared with the control group. (B) STAT3, pY-STAT3 (tyrosine phosphorylated STAT3 at the 705 residue) and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells. (C) Immunofluorescence staining showing expression of pY-STAT3 (red) in vector control or NF-YA stably overexpressed A375P cells. Nuclei were stained with DAPI (blue).
Wp1066, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/wp1066/pmc05969808-59-30-58
Average 90 stars, based on 1 article reviews
wp1066 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ApexBio wp1066 a4140
The JAK-STAT signalling pathway is involved in the inhibition of spermatogonial stem cell regeneration induced by high temperature. a The expression of the negative feedback inhibitor Socs3 in the JAK-STAT signalling pathway was upregulated 2 h after heat shock treatment, while the phosphorylation of STAT3 was reduced. The phosphorylation of Akt in the PI3K-Akt signalling pathway, which was regulated by the JAK-STAT signalling pathway, was found to be reduced. b Inhibition of the JAK/STAT signalling pathway by <t>WP1066</t> in non-treated SSCs induced a decrease in proliferation. The asterisk indicates a significant difference from the control group
Wp1066 A4140, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/wp1066+a4140/pmc06664773-110-46-53
Average 90 stars, based on 1 article reviews
wp1066 a4140 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
GlpBio Technology Inc wp1066
The JAK-STAT signalling pathway is involved in the inhibition of spermatogonial stem cell regeneration induced by high temperature. a The expression of the negative feedback inhibitor Socs3 in the JAK-STAT signalling pathway was upregulated 2 h after heat shock treatment, while the phosphorylation of STAT3 was reduced. The phosphorylation of Akt in the PI3K-Akt signalling pathway, which was regulated by the JAK-STAT signalling pathway, was found to be reduced. b Inhibition of the JAK/STAT signalling pathway by <t>WP1066</t> in non-treated SSCs induced a decrease in proliferation. The asterisk indicates a significant difference from the control group
Wp1066, supplied by GlpBio Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/wp1066/pmc10018110-37-0-3
Average 90 stars, based on 1 article reviews
wp1066 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Certara L.P wp1066
Dose escalation schema to be used prior to the occurrence of first grade ≥2 toxicity classified as possibly related to study drug.
Wp1066, supplied by Certara L.P, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/wp1066/pmc09134932-74-5-23
Average 90 stars, based on 1 article reviews
wp1066 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Adooq Bioscience LLC wp1066
Antibodies and inhibitors employed in this study
Wp1066, supplied by Adooq Bioscience LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/wp1066/pmc08364028-16-4-0
Average 90 stars, based on 1 article reviews
wp1066 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Avantor stat3 inhibitor wp1066
Antibodies and inhibitors employed in this study
Stat3 Inhibitor Wp1066, supplied by Avantor, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/stat3+inhibitor+wp1066/pm35708907-229-13-18
Average 90 stars, based on 1 article reviews
stat3 inhibitor wp1066 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Beijing CWBio rna extraction kit, fluorescence quantitative pcr kit, jak inhibitor wp1066, stat inhibitor socs3
Antibodies and inhibitors employed in this study
Rna Extraction Kit, Fluorescence Quantitative Pcr Kit, Jak Inhibitor Wp1066, Stat Inhibitor Socs3, supplied by Beijing CWBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wp1066/rna+extraction+kit++fluorescence+quantitative+pcr+kit++jak+inhibitor+wp1066++stat+inhibitor+socs3/pmc05446523-70-34-40
Average 90 stars, based on 1 article reviews
rna extraction kit, fluorescence quantitative pcr kit, jak inhibitor wp1066, stat inhibitor socs3 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Schema of the treatment of immunocompetent mice that underwent i.c. implantation of GL261 glioma cells. Seven days after GL261 implantation, mice were treated with WP1066 (60 mg/kg) by oral gavage (o.g.) 3 times per week (M/W/F) for 3 weeks. On day 7, mice were treated intratumorally with the STING agonist 8803 (5 μg). The survival rate of C57BL/6J mice was estimated by the Kaplan-Meier method. Control: 11 mice (median survival [MS]: 18 days), WP1066: 8 mice (MS: 21 days), 8803: 8 mice (MS: 143.5 days); 4 long-term survivor), WP1066 + 8803 agonist: 7 mice (MS: 25 days). Statistics (log-rank test): control versus WP1066 P = 0.0047; control versus 8803 P < 0.0001; control versus WP1066 + 8803 P = 0.0002; WP1066 versus WP1066 + 8803 P = 0.02; 8803 versus WP1066 + 8803 P = 0.0005; 8803 versus WP1066 P < 0.0001. ( B ) In vitro luciferase expression assay for the induction of IFN responses. Various concentrations of the STING agonist 8803 were used to induce the luciferase expression in the top panels. A physiological (2 μM) and a high dose (5 μM) of WP1066 was used in combination. Direct cellular cytotoxicity was measured during the above experimental conditions (lower panels). At a WP1066 concentration of 5 μM, there was a decrease in IFN activity, which was not attributed to cell viability. ( C ) WP1066 decreases STING protein expression in THP-1 cells in a dose-dependent manner. THP-1 cells were treated with the indicated concentrations of WP1066. Cells were collected and analyzed by Western blotting. ( D ) Ubiquitination assay of STING in THP-1 cells indicates that WP1066 induces STING ubiquitination in a dose-dependent manner. MG132, proteasome inhibitor used in all conditionsl; IB, immunoblotting; UB, ubiquitination blotting; IP, immunoprecipitation.

Journal: The Journal of Clinical Investigation

Article Title: STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

doi: 10.1172/JCI175033

Figure Lengend Snippet: ( A ) Schema of the treatment of immunocompetent mice that underwent i.c. implantation of GL261 glioma cells. Seven days after GL261 implantation, mice were treated with WP1066 (60 mg/kg) by oral gavage (o.g.) 3 times per week (M/W/F) for 3 weeks. On day 7, mice were treated intratumorally with the STING agonist 8803 (5 μg). The survival rate of C57BL/6J mice was estimated by the Kaplan-Meier method. Control: 11 mice (median survival [MS]: 18 days), WP1066: 8 mice (MS: 21 days), 8803: 8 mice (MS: 143.5 days); 4 long-term survivor), WP1066 + 8803 agonist: 7 mice (MS: 25 days). Statistics (log-rank test): control versus WP1066 P = 0.0047; control versus 8803 P < 0.0001; control versus WP1066 + 8803 P = 0.0002; WP1066 versus WP1066 + 8803 P = 0.02; 8803 versus WP1066 + 8803 P = 0.0005; 8803 versus WP1066 P < 0.0001. ( B ) In vitro luciferase expression assay for the induction of IFN responses. Various concentrations of the STING agonist 8803 were used to induce the luciferase expression in the top panels. A physiological (2 μM) and a high dose (5 μM) of WP1066 was used in combination. Direct cellular cytotoxicity was measured during the above experimental conditions (lower panels). At a WP1066 concentration of 5 μM, there was a decrease in IFN activity, which was not attributed to cell viability. ( C ) WP1066 decreases STING protein expression in THP-1 cells in a dose-dependent manner. THP-1 cells were treated with the indicated concentrations of WP1066. Cells were collected and analyzed by Western blotting. ( D ) Ubiquitination assay of STING in THP-1 cells indicates that WP1066 induces STING ubiquitination in a dose-dependent manner. MG132, proteasome inhibitor used in all conditionsl; IB, immunoblotting; UB, ubiquitination blotting; IP, immunoprecipitation.

Article Snippet: WP1066 , which blocks p-STAT3 , was supplied in-house and from Medchem Express (HY-15312).

Techniques: Control, In Vitro, Luciferase, Expressing, Concentration Assay, Activity Assay, Western Blot, Ubiquitin Proteomics, Immunoprecipitation

( A ) Schema of the treatment of immunocompetent mice that underwent i.c. implantation of either GL261 or CT-2A glioma cells. ( B ) The survival rate estimated by the Kaplan-Meier method of C57BL/6J mice implanted with GL261 and CT-2A. For the GL261 survival: control: 10 mice (median survival [MS]: 25 days), WP1066: 10 mice (MS: 30 days), 8803: 14 mice (MS: 30 days; 5 long-term survivors), WP1066 + 8803: 16 mice (MS: 71 days; 8 long-term survivors). Statistics (log-rank test): control versus WP1066 P = 0.04; control versus 8803 P = 0.01; control versus WP1066 + 8803 P < 0.0001; WP1066 versus WP1066 + 8803 P = 0.006; 8803 versus WP1066 + 8803 P = 0.32. For the CT-2A survival: control: 10 mice (MS: 28 days), WP1066: 9 mice (MS: 28 days), 8803: 14 mice (MS: 50 days; 7 long-term survivors), WP1066 + 8803: 16 mice (MS: 48 days; 8 long-term survivors). Statistics (log-rank test): control versus WP1066 P = 0.57; control versus 8803 P < 0.0001; control versus WP1066 + 8803 P < 0.0001; WP1066 versus WP1066 + 8803 P < 0.001; 8803 versus WP1066 + 8803 P = 0.95. ( C ) Schema of the treatment of immunocompetent mice that underwent i.c. implantation of either CT-2A or QPP8v (subclone) glioma cells. QPP8v tumors received 8803 (5 μg/mouse i.c. on days 7 and 17), anti–PD-1 (25 μg i.c. on days 7 and 17), and vehicle control (PBS) or anti–PD-1 (250 μg i.p. on days 7, 10, and 13) in single and combination therapies. ( D ) The survival rate estimated by the Kaplan-Meier method of C57BL/6J mice implanted with CT-2A and QPP8. For CT-2A: IgG: 10 mice (MS: 30 days); anti–PD-1: 10 mice (MS: 35 days), 8803: 10 mice (MS: 56 days, 4 long-term survivors); 8803 + anti–PD-1: 10 mice (MS: undefined, 8 long-term survivors); 8803 + IgG: 10 mice (MS: 65.5 days, 5 long-term survivors). Statistics (log-rank test): IgG versus anti–PD-1 P = 0.04; IgG versus 8803 P < 0.01; IgG versus 8803 + anti–PD-1 P < 0.0001; anti–PD-1 versus 8803 + anti–PD-1 P < 0.001; 8803 versus 8803 + anti–PD-1 P = 0.04; 8803 + IgG versus 8803 + anti–PD-1 P = 0.12. For QPP8: PBS: 10 mice (MS: 47 days); anti–PD-1: 10 mice (MS: 55 days); 8803: 10 mice (MS: 76 days, 4 long-term survivors); 8803 + anti–PD-1 (i.p.): 10 mice (MS: 95.5 days, 3 long-term survivors); 8803 + anti–PD-1 (i.c.): 10 mice (MS: 111 days, 5 long-term survivors). Statistics (log-rank test): PBS versus anti–PD-1 P = 0.164; PBS versus 8803 P < 0.0001; PBS versus 8803 + anti–PD-1 (i.p.) P = 0.0006; PBS versus 8803 + anti–PD-1 (i.c.) P < 0.0001; anti–PD-1 versus 8803 P < 0.0001; anti–PD-1 versus 8803 + anti–PD-1 (i.p.) P = 0.002; anti–PD-1 versus 8803 + anti–PD-1 (i.c.) P < 0.0001; 8803 versus 8803 + anti–PD-1 (i.c.) P = 0.57; 8803 versus 8803 + anti–PD-1 (i.p.) P = 0.85. ( E ) Multiplexed sequential immunofluorescence images of untreated CT-2A gliomas ( n = 3). Forty-eight hours after either the first (day 9) or second dose (day 16) of 8803, animals were euthanized and the brains were imaged for the following ( n = 3/group): DAPI (dark blue), GFAP (light blue), CD31 (cyan blue), STING (red), p-IRF3 (pink), CD4 + (yellow), and CD8 + (white) T cells. White boxes outline the portion shown at higher magnification in the right column of images. Scale bars: 500 μm (left 3 columns) and 50 μm (right column).

Journal: The Journal of Clinical Investigation

Article Title: STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

doi: 10.1172/JCI175033

Figure Lengend Snippet: ( A ) Schema of the treatment of immunocompetent mice that underwent i.c. implantation of either GL261 or CT-2A glioma cells. ( B ) The survival rate estimated by the Kaplan-Meier method of C57BL/6J mice implanted with GL261 and CT-2A. For the GL261 survival: control: 10 mice (median survival [MS]: 25 days), WP1066: 10 mice (MS: 30 days), 8803: 14 mice (MS: 30 days; 5 long-term survivors), WP1066 + 8803: 16 mice (MS: 71 days; 8 long-term survivors). Statistics (log-rank test): control versus WP1066 P = 0.04; control versus 8803 P = 0.01; control versus WP1066 + 8803 P < 0.0001; WP1066 versus WP1066 + 8803 P = 0.006; 8803 versus WP1066 + 8803 P = 0.32. For the CT-2A survival: control: 10 mice (MS: 28 days), WP1066: 9 mice (MS: 28 days), 8803: 14 mice (MS: 50 days; 7 long-term survivors), WP1066 + 8803: 16 mice (MS: 48 days; 8 long-term survivors). Statistics (log-rank test): control versus WP1066 P = 0.57; control versus 8803 P < 0.0001; control versus WP1066 + 8803 P < 0.0001; WP1066 versus WP1066 + 8803 P < 0.001; 8803 versus WP1066 + 8803 P = 0.95. ( C ) Schema of the treatment of immunocompetent mice that underwent i.c. implantation of either CT-2A or QPP8v (subclone) glioma cells. QPP8v tumors received 8803 (5 μg/mouse i.c. on days 7 and 17), anti–PD-1 (25 μg i.c. on days 7 and 17), and vehicle control (PBS) or anti–PD-1 (250 μg i.p. on days 7, 10, and 13) in single and combination therapies. ( D ) The survival rate estimated by the Kaplan-Meier method of C57BL/6J mice implanted with CT-2A and QPP8. For CT-2A: IgG: 10 mice (MS: 30 days); anti–PD-1: 10 mice (MS: 35 days), 8803: 10 mice (MS: 56 days, 4 long-term survivors); 8803 + anti–PD-1: 10 mice (MS: undefined, 8 long-term survivors); 8803 + IgG: 10 mice (MS: 65.5 days, 5 long-term survivors). Statistics (log-rank test): IgG versus anti–PD-1 P = 0.04; IgG versus 8803 P < 0.01; IgG versus 8803 + anti–PD-1 P < 0.0001; anti–PD-1 versus 8803 + anti–PD-1 P < 0.001; 8803 versus 8803 + anti–PD-1 P = 0.04; 8803 + IgG versus 8803 + anti–PD-1 P = 0.12. For QPP8: PBS: 10 mice (MS: 47 days); anti–PD-1: 10 mice (MS: 55 days); 8803: 10 mice (MS: 76 days, 4 long-term survivors); 8803 + anti–PD-1 (i.p.): 10 mice (MS: 95.5 days, 3 long-term survivors); 8803 + anti–PD-1 (i.c.): 10 mice (MS: 111 days, 5 long-term survivors). Statistics (log-rank test): PBS versus anti–PD-1 P = 0.164; PBS versus 8803 P < 0.0001; PBS versus 8803 + anti–PD-1 (i.p.) P = 0.0006; PBS versus 8803 + anti–PD-1 (i.c.) P < 0.0001; anti–PD-1 versus 8803 P < 0.0001; anti–PD-1 versus 8803 + anti–PD-1 (i.p.) P = 0.002; anti–PD-1 versus 8803 + anti–PD-1 (i.c.) P < 0.0001; 8803 versus 8803 + anti–PD-1 (i.c.) P = 0.57; 8803 versus 8803 + anti–PD-1 (i.p.) P = 0.85. ( E ) Multiplexed sequential immunofluorescence images of untreated CT-2A gliomas ( n = 3). Forty-eight hours after either the first (day 9) or second dose (day 16) of 8803, animals were euthanized and the brains were imaged for the following ( n = 3/group): DAPI (dark blue), GFAP (light blue), CD31 (cyan blue), STING (red), p-IRF3 (pink), CD4 + (yellow), and CD8 + (white) T cells. White boxes outline the portion shown at higher magnification in the right column of images. Scale bars: 500 μm (left 3 columns) and 50 μm (right column).

Article Snippet: WP1066 , which blocks p-STAT3 , was supplied in-house and from Medchem Express (HY-15312).

Techniques: Control, Immunofluorescence

IL-6 promotes LUAD progression by activating the JAK2/STAT3 pathway in M2-like macrophages. a GSVA analysis of differential pathways between AMs, TAMs in early and advanced LUAd. b Effects of IL-6 stimulation on common pathway expression in TAMs detected by western blot analysis. c Expression of the JAK2/STAT3 pathway with IL-6-stimulated, IL-6-stimulated with the addition of IL-6-NA in M2-like macrophages were analyzed by western blot. d Effect of AZD1480 and WP1066 on JAK2/STAT3 pathway expression in THP1 derived M2-like macrophages after IL-6 stimulation were analyzed by western blot. e Cell migration and invasion ability of LUAD cells alone, co-culture with M2-like macrophages or co-culture with M2-like macrophages followed by addition of AZD1480 and WP1066 was determined by the transwell assay. f RT-qPCR and Elisa analysis showed IL-6 expression in M2-like macrophages after IL-6 stimulation or IL-6 stimulation with the addition of AZD1480 and WP1066 (Left: Elisa results. Right: RT-qPCR results). g IL-6 expression after STAT3 overexpression or knockdown was analyzed by western blot. h RT-qPCR and Elisa analysis showed IL-6 expression in M2-like macrophages after STAT3 overexpression or knockdown

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma

doi: 10.1186/s13046-024-02989-x

Figure Lengend Snippet: IL-6 promotes LUAD progression by activating the JAK2/STAT3 pathway in M2-like macrophages. a GSVA analysis of differential pathways between AMs, TAMs in early and advanced LUAd. b Effects of IL-6 stimulation on common pathway expression in TAMs detected by western blot analysis. c Expression of the JAK2/STAT3 pathway with IL-6-stimulated, IL-6-stimulated with the addition of IL-6-NA in M2-like macrophages were analyzed by western blot. d Effect of AZD1480 and WP1066 on JAK2/STAT3 pathway expression in THP1 derived M2-like macrophages after IL-6 stimulation were analyzed by western blot. e Cell migration and invasion ability of LUAD cells alone, co-culture with M2-like macrophages or co-culture with M2-like macrophages followed by addition of AZD1480 and WP1066 was determined by the transwell assay. f RT-qPCR and Elisa analysis showed IL-6 expression in M2-like macrophages after IL-6 stimulation or IL-6 stimulation with the addition of AZD1480 and WP1066 (Left: Elisa results. Right: RT-qPCR results). g IL-6 expression after STAT3 overexpression or knockdown was analyzed by western blot. h RT-qPCR and Elisa analysis showed IL-6 expression in M2-like macrophages after STAT3 overexpression or knockdown

Article Snippet: JAK2/STAT3 inhibitor, WP1066 10 μM (TargetMol, T2156, MA, USA).

Techniques: Analysis, Expressing, Western Blot, Derivative Assay, Migration, Co-culture Assay, Transwell Assay, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Over Expression, Knockdown, Real-time Polymerase Chain Reaction

Figure 3. NF-YA increases the expression of VEGF and activity of STAT3. (A) NF-YA, VEGF and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells (left panel); relative mRNA expression of VEGF in vector control or NF-YA stably overexpressed A375P/Malme-3M cells by real-time quantitative PCR (left panel), *P<0.003 compared with the control group. (B) STAT3, pY-STAT3 (tyrosine phosphorylated STAT3 at the 705 residue) and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells. (C) Immunofluorescence staining showing expression of pY-STAT3 (red) in vector control or NF-YA stably overexpressed A375P cells. Nuclei were stained with DAPI (blue).

Journal: Oncology reports

Article Title: NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells.

doi: 10.3892/or.2016.4761

Figure Lengend Snippet: Figure 3. NF-YA increases the expression of VEGF and activity of STAT3. (A) NF-YA, VEGF and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells (left panel); relative mRNA expression of VEGF in vector control or NF-YA stably overexpressed A375P/Malme-3M cells by real-time quantitative PCR (left panel), *P<0.003 compared with the control group. (B) STAT3, pY-STAT3 (tyrosine phosphorylated STAT3 at the 705 residue) and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells. (C) Immunofluorescence staining showing expression of pY-STAT3 (red) in vector control or NF-YA stably overexpressed A375P cells. Nuclei were stained with DAPI (blue).

Article Snippet: STAT3 inhibitor WP1066 (working concentration: 5 μM) was purchased from Selleck Chemicals (cat no. S2796; Houston, TX, uSA).

Techniques: Expressing, Activity Assay, Western Blot, Plasmid Preparation, Control, Stable Transfection, Real-time Polymerase Chain Reaction, Residue, Immunofluorescence, Staining

Figure 4. NF-YA upregulated VEGF in a STAT3-dependent manner. (A) NF-YA, STAT3, pY-STAT3, VEGF and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed (or NF-YA stably overexpressed plus STAT3 inhibitor WP1066 treatment) A375P/Malme-3M cells. (B) EZH2 and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells (upper panel). Relative mRNA expression of VEGF in vector control or NF-YA stably overexpressed A375P/Malme-3M cells by real-time quantitative PCR (low panel), *P<0.004 compared with the control group. (C) NF-YA, EZH2, STAT3, pY-STAT3, VEGF and β-actin protein levels were detected by western blot analysis in scramble control or NF-YA stably knockdown (sh-1-N, sh-2-N) A375-M2 cells.

Journal: Oncology reports

Article Title: NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells.

doi: 10.3892/or.2016.4761

Figure Lengend Snippet: Figure 4. NF-YA upregulated VEGF in a STAT3-dependent manner. (A) NF-YA, STAT3, pY-STAT3, VEGF and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed (or NF-YA stably overexpressed plus STAT3 inhibitor WP1066 treatment) A375P/Malme-3M cells. (B) EZH2 and β-actin protein levels were detected by western blot analysis in vector control or NF-YA stably overexpressed A375P/Malme-3M cells (upper panel). Relative mRNA expression of VEGF in vector control or NF-YA stably overexpressed A375P/Malme-3M cells by real-time quantitative PCR (low panel), *P<0.004 compared with the control group. (C) NF-YA, EZH2, STAT3, pY-STAT3, VEGF and β-actin protein levels were detected by western blot analysis in scramble control or NF-YA stably knockdown (sh-1-N, sh-2-N) A375-M2 cells.

Article Snippet: STAT3 inhibitor WP1066 (working concentration: 5 μM) was purchased from Selleck Chemicals (cat no. S2796; Houston, TX, uSA).

Techniques: Western Blot, Plasmid Preparation, Control, Stable Transfection, Expressing, Real-time Polymerase Chain Reaction, Knockdown

Figure 5. The role of EZH2 in NF-YA induced VEGF expression and STAT3 activation. (A) Immunoprecipitation of STAT3 protein using antibodies for STAT3 (IP), or a non-specific immunoglobulin G (IgG) from scramble control or NF-YA stably knockdown (sh-1-N) A375-M2 cells, followed by immunoblots with the indicated antibodies. Methy-K, means rabbit anti-methylated lysine antibody; input indicate 5% of pre-immunoprecipitated samples. (B) NF-YA, EZH2, STAT3, pY-STAT3, VEGF and β-actin protein levels were detected by western blot analysis in scramble control or EZH2 stably knockdown (sh-1-E, sh-2-E) A375P cells (left panel); immunoprecipitation of STAT3 protein using antibodies for STAT3 (IP), or a non-specific immunoglobulin G (IgG) from scramble control or EZH2 stably knockdown (sh-2-E) A375P cells, followed by immunoblots with the indicated antibodies. Methy-K, means rabbit anti- methylated lysine antibody; input indicate 5% of pre-immunoprecipitated samples (middle panel); NF-YA, STAT3, pY-STAT3, VEGF and β-actin protein levels were detected by western blot analysis in vector control and NF-YA stably overexpressed A375P cells with EZH2 stably knockdown (sh-2-E) (right panel). (C) The vector control or NF-YA stably overexpressed A375P-sh-2-E cells were seeded in a Matrigel‑coated upper chamber. Cells invaded through the Matrigel after incubation for 24 h was detected by H&E staining and quantified (lower panel). Data expression was analyzed by quantification of six randomly selected fields. A375P-sh-2-E, means A375P cells with EZH2 stably knockdown (sh-2-E). (D) HUVECs cells were plated in the upper chamber coated with Matrigel in Transwell filters (0.4 µm). The vector control or NF-YA stably overexpressed A375P-sh-2-E cells were grown in the lower chamber. Cultured for 3 days, the tube-like structures that formed in the gel were photographed (magnification, x100).

Journal: Oncology reports

Article Title: NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells.

doi: 10.3892/or.2016.4761

Figure Lengend Snippet: Figure 5. The role of EZH2 in NF-YA induced VEGF expression and STAT3 activation. (A) Immunoprecipitation of STAT3 protein using antibodies for STAT3 (IP), or a non-specific immunoglobulin G (IgG) from scramble control or NF-YA stably knockdown (sh-1-N) A375-M2 cells, followed by immunoblots with the indicated antibodies. Methy-K, means rabbit anti-methylated lysine antibody; input indicate 5% of pre-immunoprecipitated samples. (B) NF-YA, EZH2, STAT3, pY-STAT3, VEGF and β-actin protein levels were detected by western blot analysis in scramble control or EZH2 stably knockdown (sh-1-E, sh-2-E) A375P cells (left panel); immunoprecipitation of STAT3 protein using antibodies for STAT3 (IP), or a non-specific immunoglobulin G (IgG) from scramble control or EZH2 stably knockdown (sh-2-E) A375P cells, followed by immunoblots with the indicated antibodies. Methy-K, means rabbit anti- methylated lysine antibody; input indicate 5% of pre-immunoprecipitated samples (middle panel); NF-YA, STAT3, pY-STAT3, VEGF and β-actin protein levels were detected by western blot analysis in vector control and NF-YA stably overexpressed A375P cells with EZH2 stably knockdown (sh-2-E) (right panel). (C) The vector control or NF-YA stably overexpressed A375P-sh-2-E cells were seeded in a Matrigel‑coated upper chamber. Cells invaded through the Matrigel after incubation for 24 h was detected by H&E staining and quantified (lower panel). Data expression was analyzed by quantification of six randomly selected fields. A375P-sh-2-E, means A375P cells with EZH2 stably knockdown (sh-2-E). (D) HUVECs cells were plated in the upper chamber coated with Matrigel in Transwell filters (0.4 µm). The vector control or NF-YA stably overexpressed A375P-sh-2-E cells were grown in the lower chamber. Cultured for 3 days, the tube-like structures that formed in the gel were photographed (magnification, x100).

Article Snippet: STAT3 inhibitor WP1066 (working concentration: 5 μM) was purchased from Selleck Chemicals (cat no. S2796; Houston, TX, uSA).

Techniques: Expressing, Activation Assay, Immunoprecipitation, Control, Stable Transfection, Knockdown, Western Blot, Methylation, Plasmid Preparation, Incubation, Staining, Cell Culture

The JAK-STAT signalling pathway is involved in the inhibition of spermatogonial stem cell regeneration induced by high temperature. a The expression of the negative feedback inhibitor Socs3 in the JAK-STAT signalling pathway was upregulated 2 h after heat shock treatment, while the phosphorylation of STAT3 was reduced. The phosphorylation of Akt in the PI3K-Akt signalling pathway, which was regulated by the JAK-STAT signalling pathway, was found to be reduced. b Inhibition of the JAK/STAT signalling pathway by WP1066 in non-treated SSCs induced a decrease in proliferation. The asterisk indicates a significant difference from the control group

Journal: Stem Cell Research & Therapy

Article Title: High temperature suppressed SSC self-renewal through S phase cell cycle arrest but not apoptosis

doi: 10.1186/s13287-019-1335-5

Figure Lengend Snippet: The JAK-STAT signalling pathway is involved in the inhibition of spermatogonial stem cell regeneration induced by high temperature. a The expression of the negative feedback inhibitor Socs3 in the JAK-STAT signalling pathway was upregulated 2 h after heat shock treatment, while the phosphorylation of STAT3 was reduced. The phosphorylation of Akt in the PI3K-Akt signalling pathway, which was regulated by the JAK-STAT signalling pathway, was found to be reduced. b Inhibition of the JAK/STAT signalling pathway by WP1066 in non-treated SSCs induced a decrease in proliferation. The asterisk indicates a significant difference from the control group

Article Snippet: SSCs were plated at a density of 2 × 10 3 cells/well in 96-well plates, cultured for 2 h, washed with medium and then cultured for an additional 20 h in SSC medium in the presence or absence of 1.25 μM, 2.5 μM or 5 μM WP1066 (A JAK-STAT signalling pathway inhibitor; A4140, APExBIO).

Techniques: Inhibition, Expressing, Phospho-proteomics, Control

Dose escalation schema to be used prior to the occurrence of first grade ≥2 toxicity classified as possibly related to study drug.

Journal: CNS Oncology

Article Title: A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma

doi: 10.2217/cns-2022-0005

Figure Lengend Snippet: Dose escalation schema to be used prior to the occurrence of first grade ≥2 toxicity classified as possibly related to study drug.

Article Snippet: Individual plasma concentration-time data for WP1066 was used to generate pharmacokinetic parameter estimates, using both compartmental and non-compartmental methods utilizing WinNonLin Professional 5.3 (Pharsight Corp., MO, USA).

Techniques:

Demographic and outcome data of patients treated with  WP1066.

Journal: CNS Oncology

Article Title: A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma

doi: 10.2217/cns-2022-0005

Figure Lengend Snippet: Demographic and outcome data of patients treated with WP1066.

Article Snippet: Individual plasma concentration-time data for WP1066 was used to generate pharmacokinetic parameter estimates, using both compartmental and non-compartmental methods utilizing WinNonLin Professional 5.3 (Pharsight Corp., MO, USA).

Techniques: Mutagenesis

(A) Representative image of the glioma microenvironment at the time of initial diagnosis demonstrating relative rare infiltration of CD3 + T cells and the (B) heterogeneity of p-STAT3 expression at 40× magnification (subject 1). Immunohistochemical (IHC) analysis was used to detect membrane expression of CD3 on T cells and nuclear expression of p-STAT3 in all subjects enrolled (n = 8). (C) Representative flow cytometry image showing the mean fluorescent intensity (MFI) of intracellular p-STAT3 in PBMCs relative to isotype controls at baseline before administration of WP1066 and at 172 h (subject 1). Positive p-STAT3 expression was defined based on the isotype controls. (D) The percentage of p-STAT3+ PBMCs were then quantified longitudinally by flow cytometry. The percentage of p-STAT3+ PBMCs were graphed for each enrolled subject over time (top panel) and based as a mean with SEM of the entire group at each time point on a scatter plot (bottom panel). There was a statistical difference after 172 h of dosing by paired t-test (p = 0.0219). Statistical significance was not yet reached at 4, 24 or 168 h. FSC-H: Forward scatter parameter H; PBMC: Peripheral blood mononuclear cell; PE: Phycoerythrin fluorophore.

Journal: CNS Oncology

Article Title: A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma

doi: 10.2217/cns-2022-0005

Figure Lengend Snippet: (A) Representative image of the glioma microenvironment at the time of initial diagnosis demonstrating relative rare infiltration of CD3 + T cells and the (B) heterogeneity of p-STAT3 expression at 40× magnification (subject 1). Immunohistochemical (IHC) analysis was used to detect membrane expression of CD3 on T cells and nuclear expression of p-STAT3 in all subjects enrolled (n = 8). (C) Representative flow cytometry image showing the mean fluorescent intensity (MFI) of intracellular p-STAT3 in PBMCs relative to isotype controls at baseline before administration of WP1066 and at 172 h (subject 1). Positive p-STAT3 expression was defined based on the isotype controls. (D) The percentage of p-STAT3+ PBMCs were then quantified longitudinally by flow cytometry. The percentage of p-STAT3+ PBMCs were graphed for each enrolled subject over time (top panel) and based as a mean with SEM of the entire group at each time point on a scatter plot (bottom panel). There was a statistical difference after 172 h of dosing by paired t-test (p = 0.0219). Statistical significance was not yet reached at 4, 24 or 168 h. FSC-H: Forward scatter parameter H; PBMC: Peripheral blood mononuclear cell; PE: Phycoerythrin fluorophore.

Article Snippet: Individual plasma concentration-time data for WP1066 was used to generate pharmacokinetic parameter estimates, using both compartmental and non-compartmental methods utilizing WinNonLin Professional 5.3 (Pharsight Corp., MO, USA).

Techniques: Expressing, Immunohistochemical staining, Flow Cytometry

Immune analysis cohort.

Journal: CNS Oncology

Article Title: A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma

doi: 10.2217/cns-2022-0005

Figure Lengend Snippet: Immune analysis cohort.

Article Snippet: Individual plasma concentration-time data for WP1066 was used to generate pharmacokinetic parameter estimates, using both compartmental and non-compartmental methods utilizing WinNonLin Professional 5.3 (Pharsight Corp., MO, USA).

Techniques:

Antibodies and inhibitors employed in this study

Journal: Cell Communication and Signaling : CCS

Article Title: PI3K-AKT, JAK2-STAT3 pathways and cell–cell contact regulate maspin subcellular localization

doi: 10.1186/s12964-021-00758-3

Figure Lengend Snippet: Antibodies and inhibitors employed in this study

Article Snippet: AdooQ Biosciences (#A11795) , WP1066 , JAK2/STAT3 , 10 μM.

Techniques:

EGF-induced maspin nuclear accumulation depends on the PI3K-Akt and JAK2-STAT3 pathways A Starved MCF-10A cells were pretreated with inhibitors of EGFR (Gefitinib), PI3K (Wortmannin), pan-PKC (Go6983), JAK2/STAT3 (WP1066), H/K-Ras (FTI-277) and Src family kinases (PP2) (except for the upper row), for 30 min followed by 20 ng/ml EGF treatment for additional 1 h. Maspin localization was analyzed by immunofluorescence with anti-maspin antibody. Nuclei were stained with DAPI. B Cells were quantified based on the criteria shown next to the graph * p < 0.05 (Chi-square test). C The experiment described in A was repeated and images were acquired in a higher resolution. JAK2/STAT3 inhibition by WP1066 leads to a junctional discontinuity pattern, whereas PI3K inhibition by Wortmannin results in continuous maspin distribution across cell–cell junctions (arrows). Images are representative of at least three independent assays. Scale bar: 20 µm

Journal: Cell Communication and Signaling : CCS

Article Title: PI3K-AKT, JAK2-STAT3 pathways and cell–cell contact regulate maspin subcellular localization

doi: 10.1186/s12964-021-00758-3

Figure Lengend Snippet: EGF-induced maspin nuclear accumulation depends on the PI3K-Akt and JAK2-STAT3 pathways A Starved MCF-10A cells were pretreated with inhibitors of EGFR (Gefitinib), PI3K (Wortmannin), pan-PKC (Go6983), JAK2/STAT3 (WP1066), H/K-Ras (FTI-277) and Src family kinases (PP2) (except for the upper row), for 30 min followed by 20 ng/ml EGF treatment for additional 1 h. Maspin localization was analyzed by immunofluorescence with anti-maspin antibody. Nuclei were stained with DAPI. B Cells were quantified based on the criteria shown next to the graph * p < 0.05 (Chi-square test). C The experiment described in A was repeated and images were acquired in a higher resolution. JAK2/STAT3 inhibition by WP1066 leads to a junctional discontinuity pattern, whereas PI3K inhibition by Wortmannin results in continuous maspin distribution across cell–cell junctions (arrows). Images are representative of at least three independent assays. Scale bar: 20 µm

Article Snippet: AdooQ Biosciences (#A11795) , WP1066 , JAK2/STAT3 , 10 μM.

Techniques: Immunofluorescence, Staining, Inhibition